2025-09-09 - Analysis Report
Okay, here's an analysis of Tempus AI (TEM) based on the provided data.

## TEM (Unknown Company) Analysis

**Company Overview:** Tempus AI is focused on leveraging AI to enhance clinical care, particularly in the healthcare sector.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (TEM):** 44.22%
*   **Cumulative Return (VOO):** 20.27%
*   **Absolute Divergence:** 23.3%
*   **Relative Divergence:** 38.0 (Indicates TEM's performance is in the 38th percentile of its historical divergence range compared to VOO.)
*   **Analysis:** TEM has significantly outperformed the S&P 500.  The relative divergence suggests the current outperformance is positioned in the lower end relative to its historical performance against the S&P500.

**Alpha, Beta Analysis**

| Year      | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
| :---------- | :------ | :------ | :------ | :----- | :----- |
| 2023-2025 | 44.0%   | 75.0%   | 25.0%   | -0.0   | 13.9   |

*   **CAGR:**  A strong 44% Compound Annual Growth Rate indicates robust growth over the period.
*   **MDD:** A very high Maximum Drawdown of 75% indicates high volatility and potential for significant losses.
*   **Alpha:** A positive Alpha of 25.0% shows that TEM has outperformed its benchmark, indicating added value.
*   **Beta:** A Beta of -0.0 suggests TEM's returns are not correlated with the overall market (S&P 500).
*   **Cap(B):** The market capitalization of 13.9 Billion.

### 2. Recent Stock Price Movement

*   **Current Price:** $79.62
*   **Last Market Close:** $80.22 (Change: +$0.75)
*   **5-Day Moving Average:** $77.555
*   **20-Day Moving Average:** $73.5968
*   **60-Day Moving Average:** $65.9958

*   **Analysis:** The price is above all moving averages, indicating an uptrend. The positive change in the last market close suggests upward momentum.

### 3. Market Risk Indicator and Indexes

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 58.30 (Neutral)
*   **PPO:** 0.0334 (Positive, indicating potential upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Delta_Previous_Relative_Divergence (20-day):** +7.4 (Short-term increase, bullish)
*   **Expected Return:** NaN

*   **Analysis:** The MRI suggests low market risk. RSI is neutral. PPO indicates positive momentum. The Hybrid Signal suggests a buy with caution due to the MRI. The increase in relative divergence confirms a short-term upward trend.  The "price" information implies a recent, albeit small, jump in price, suggesting the price is reacting positively to recent news.

### 4. Recent News & Significant Events

*   **Partnership with Northwestern Medicine:**  Integration of Tempus' AI co-pilot into their EHR platform.
*   **Participation in Morgan Stanley Healthcare Conference:** Increased visibility and potential investor interest.
*   **HC Wainwright Initiates Buy Rating:** Positive analyst coverage with a $90 price target.
*   **Acquisition of Paige:** Expansion into digital pathology.

*   **Analysis:** The news is overwhelmingly positive, focusing on partnerships, AI advancements, analyst upgrades, and strategic acquisitions. These events are likely contributing to the recent upward price movement.

#### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 2.15)
*   **Opinions:** 11
*   **Target Price:** $72.73 (Avg), $90.00 (High), $60.00 (Low)
*   **Analysis:** The analyst consensus is bullish, with a 'Buy' recommendation. The average target price is below the current price, but the high target price indicates some analysts see further upside.

### 5. Recent Earnings Analysis

| Date       | EPS   | Expected EPS |
| :----------- | :---- | :------------- |
| 2025-08-08 | -0.22 | -0.23          |
| 2025-05-06 | -0.24 | -0.26003       |
| 2025-02-24 | -0.18 | -0.15          |
| 2024-11-04 | -0.25 | -0.26608       |
| 2024-08-06 | -0.63 | -0.59          |

*   **Analysis:** Tempus AI has consistently reported negative EPS, but it has frequently beaten expectations. This suggests potential for future profitability.

### 6. Financial Information

| Quarter    | Revenue | Profit Margin |
| :----------- | :------- | :-------------- |
| 2025-06-30 | $0.31B  | 61.99%          |
| 2025-03-31 | $0.26B  | 60.69%          |
| 2024-12-31 | $0.20B  | 60.83%          |
| 2024-09-30 | $0.18B  | 58.50%          |
| 2024-06-30 | $0.17B  | 45.50%          |

| Quarter    | Equity | ROE       |
| :----------- | :------- | :---------- |
| 2025-06-30 | $0.31B  | -13.84%   |
| 2025-03-31 | $0.33B  | -20.86%   |
| 2024-12-31 | $0.06B  | -23.10%   |
| 2024-09-30 | $0.05B  | -141.16%  |
| 2024-06-30 | $0.10B  | -562.04%  |

*   **Analysis:** Revenue is growing consistently, and profit margins are high and improving. However, the Return on Equity (ROE) is negative, indicating the company is not generating profits from its equity.

### 7. Summary Analysis

**Overall:** Tempus AI presents a mixed picture.

*   **Positives:** Strong revenue growth, high and increasing profit margins, positive news flow (partnerships, acquisitions, analyst upgrades), outperformance of the S&P 500, positive short-term momentum, and a "Buy" analyst consensus.
*   **Negatives:**  Negative EPS and ROE, indicating a lack of current profitability. High Maximum Drawdown suggests high volatility.

**Conclusion:** Tempus AI appears to be a high-growth, potentially high-risk investment. The company is investing heavily in growth and has a strong market position in AI-powered healthcare.  The key to future success will be its ability to translate revenue growth into profitability. The high MDD warrants caution, and investors should be prepared for potential price swings.
